JPWO2021181366A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021181366A5 JPWO2021181366A5 JP2022554748A JP2022554748A JPWO2021181366A5 JP WO2021181366 A5 JPWO2021181366 A5 JP WO2021181366A5 JP 2022554748 A JP2022554748 A JP 2022554748A JP 2022554748 A JP2022554748 A JP 2022554748A JP WO2021181366 A5 JPWO2021181366 A5 JP WO2021181366A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- constant region
- fragment
- isolated protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 101
- 108090000623 proteins and genes Proteins 0.000 claims description 101
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 58
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 58
- 239000012634 fragment Substances 0.000 claims description 38
- 239000000427 antigen Substances 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 25
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 210000004698 lymphocyte Anatomy 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims description 6
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 3
- 102100025430 Butyrophilin-like protein 3 Human genes 0.000 claims description 2
- 102100025371 Butyrophilin-like protein 8 Human genes 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 2
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 claims description 2
- 101000934741 Homo sapiens Butyrophilin-like protein 3 Proteins 0.000 claims description 2
- 101000934742 Homo sapiens Butyrophilin-like protein 8 Proteins 0.000 claims description 2
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 claims description 2
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101000680681 Homo sapiens T cell receptor gamma variable 9 Proteins 0.000 claims description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 2
- -1 KI2L4 Proteins 0.000 claims description 2
- 101150074862 KLRC3 gene Proteins 0.000 claims description 2
- 101150018199 KLRC4 gene Proteins 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 claims description 2
- 102100022700 NKG2-F type II integral membrane protein Human genes 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100022393 T cell receptor gamma variable 9 Human genes 0.000 claims description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 3
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 238000009167 androgen deprivation therapy Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000012650 click reaction Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 description 1
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 1
- 101710156660 T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989230P | 2020-03-13 | 2020-03-13 | |
| US202062989120P | 2020-03-13 | 2020-03-13 | |
| US202062989187P | 2020-03-13 | 2020-03-13 | |
| US202062989093P | 2020-03-13 | 2020-03-13 | |
| US202062989071P | 2020-03-13 | 2020-03-13 | |
| US62/989,230 | 2020-03-13 | ||
| US62/989,071 | 2020-03-13 | ||
| US62/989,187 | 2020-03-13 | ||
| US62/989,120 | 2020-03-13 | ||
| US62/989,093 | 2020-03-13 | ||
| PCT/IB2021/052121 WO2021181366A1 (en) | 2020-03-13 | 2021-03-15 | Materials and methods for binding siglec-3/cd33 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023517660A JP2023517660A (ja) | 2023-04-26 |
| JP2023517660A5 JP2023517660A5 (https=) | 2024-03-19 |
| JPWO2021181366A5 true JPWO2021181366A5 (https=) | 2024-03-19 |
Family
ID=75108687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554748A Pending JP2023517660A (ja) | 2020-03-13 | 2021-03-15 | シグレック３／ｃｄ３３に結合させるための材料及び方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20240293453A1 (https=) |
| EP (4) | EP4233893A3 (https=) |
| JP (1) | JP2023517660A (https=) |
| KR (4) | KR20220154728A (https=) |
| CN (1) | CN115768482A (https=) |
| AR (3) | AR129167A2 (https=) |
| AU (4) | AU2021235564A1 (https=) |
| BR (1) | BR112022018176A2 (https=) |
| CA (1) | CA3171113A1 (https=) |
| CL (4) | CL2022002488A1 (https=) |
| CO (1) | CO2022013823A2 (https=) |
| EC (1) | ECSP22071278A (https=) |
| IL (4) | IL302347A (https=) |
| JO (1) | JOP20220220A1 (https=) |
| MX (1) | MX2022011320A (https=) |
| PE (4) | PE20240019A1 (https=) |
| PH (1) | PH12022552370A1 (https=) |
| TW (1) | TW202144418A (https=) |
| UY (4) | UY40278A (https=) |
| WO (1) | WO2021181366A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220147631A (ko) * | 2020-02-27 | 2022-11-03 | 얀센 바이오테크 인코포레이티드 | 면역 반응을 조절하기 위한 물질 및 방법 |
| WO2023037333A1 (en) * | 2021-09-13 | 2023-03-16 | Janssen Biotech, Inc | CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER |
| KR20240101640A (ko) * | 2021-11-12 | 2024-07-02 | 얀센 바이오테크 인코포레이티드 | 면역 세포의 향상된 확장 및 사용을 위한 재료 및 방법 |
| WO2025120583A2 (en) * | 2023-12-08 | 2025-06-12 | Janssen Biotech, Inc. | CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF |
| WO2026006719A1 (en) * | 2024-06-28 | 2026-01-02 | IN8bio, Inc. | Multifunctional molecules and methods of treatment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CA2671949C (en) | 2006-12-18 | 2011-11-01 | Arigen Pharmaceuticals, Inc. | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US10344050B2 (en) | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| KR102216003B1 (ko) | 2013-03-15 | 2021-02-16 | 얀센 바이오테크 인코포레이티드 | 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법 |
| JO3568B1 (ar) | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP7497953B2 (ja) * | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| CA3076099A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | Linkers for chimeric antigen receptors |
| EP3727474A1 (en) | 2017-12-18 | 2020-10-28 | Janssen Biotech, Inc. | Radiolabeling of polypeptides |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
-
2021
- 2021-03-15 KR KR1020227035280A patent/KR20220154728A/ko not_active Withdrawn
- 2021-03-15 TW TW110109226A patent/TW202144418A/zh unknown
- 2021-03-15 UY UY0001040278A patent/UY40278A/es unknown
- 2021-03-15 IL IL302347A patent/IL302347A/en unknown
- 2021-03-15 PE PE2023001646A patent/PE20240019A1/es unknown
- 2021-03-15 UY UY0001040279A patent/UY40279A/es unknown
- 2021-03-15 MX MX2022011320A patent/MX2022011320A/es unknown
- 2021-03-15 EP EP23160422.4A patent/EP4233893A3/en not_active Withdrawn
- 2021-03-15 KR KR1020237011668A patent/KR20230051616A/ko active Pending
- 2021-03-15 UY UY0001040280A patent/UY40280A/es unknown
- 2021-03-15 PE PE2023001668A patent/PE20240020A1/es unknown
- 2021-03-15 US US17/906,040 patent/US20240293453A1/en active Pending
- 2021-03-15 KR KR1020237011669A patent/KR20230051617A/ko active Pending
- 2021-03-15 CN CN202180020162.XA patent/CN115768482A/zh active Pending
- 2021-03-15 KR KR1020237011667A patent/KR20230051615A/ko active Pending
- 2021-03-15 EP EP21713138.2A patent/EP4117715A1/en active Pending
- 2021-03-15 IL IL302349A patent/IL302349A/en unknown
- 2021-03-15 UY UY0001039130A patent/UY39130A/es unknown
- 2021-03-15 WO PCT/IB2021/052121 patent/WO2021181366A1/en not_active Ceased
- 2021-03-15 BR BR112022018176A patent/BR112022018176A2/pt unknown
- 2021-03-15 EP EP23160439.8A patent/EP4233895A3/en not_active Withdrawn
- 2021-03-15 CA CA3171113A patent/CA3171113A1/en active Pending
- 2021-03-15 PH PH1/2022/552370A patent/PH12022552370A1/en unknown
- 2021-03-15 IL IL302351A patent/IL302351A/en unknown
- 2021-03-15 EP EP23160428.1A patent/EP4233894A3/en not_active Withdrawn
- 2021-03-15 PE PE2022001955A patent/PE20230001A1/es unknown
- 2021-03-15 IL IL296263A patent/IL296263A/en unknown
- 2021-03-15 AU AU2021235564A patent/AU2021235564A1/en active Pending
- 2021-03-15 JP JP2022554748A patent/JP2023517660A/ja active Pending
- 2021-03-15 PE PE2023001651A patent/PE20231517A1/es unknown
-
2022
- 2022-09-12 CL CL2022002488A patent/CL2022002488A1/es unknown
- 2022-09-13 JO JOP/2022/0220A patent/JOP20220220A1/ar unknown
- 2022-09-13 EC ECSENADI202271278A patent/ECSP22071278A/es unknown
- 2022-09-27 CO CONC2022/0013823A patent/CO2022013823A2/es unknown
-
2023
- 2023-03-29 CL CL2023000909A patent/CL2023000909A1/es unknown
- 2023-03-29 CL CL2023000911A patent/CL2023000911A1/es unknown
- 2023-03-29 CL CL2023000910A patent/CL2023000910A1/es unknown
- 2023-04-26 AU AU2023202520A patent/AU2023202520A1/en not_active Abandoned
- 2023-04-26 US US18/307,076 patent/US20230365683A1/en active Pending
- 2023-04-26 US US18/307,127 patent/US20230365684A1/en active Pending
- 2023-04-26 US US18/307,146 patent/US20230250171A1/en active Pending
- 2023-04-27 AU AU2023202536A patent/AU2023202536A1/en not_active Abandoned
- 2023-04-27 AR ARP230101026A patent/AR129167A2/es unknown
- 2023-04-27 AR ARP230101028A patent/AR129169A2/es unknown
- 2023-04-27 AU AU2023202538A patent/AU2023202538A1/en not_active Abandoned
- 2023-04-27 AR ARP230101027A patent/AR129168A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11202828B2 (en) | Therapeutic SIRP-α antibodies | |
| RU2767357C2 (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| JP2021063082A (ja) | Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物 | |
| WO2015063187A1 (en) | Multivalent antigen-binding proteins | |
| TW201702265A (zh) | 結合lag-3的分子和其使用方法 | |
| CN116333138A (zh) | Pd-1结合分子和其使用方法 | |
| IL294017A (en) | Materials and methods for in vivo biological targeting | |
| TWI814715B (zh) | Ａｄａｍ９結合分子及使用其的方法 | |
| US20230279108A1 (en) | Therapeutic sirp-alpha antibodies | |
| CA3228641A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| JP2021505637A (ja) | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 | |
| JPWO2021019389A5 (https=) | ||
| US20240336686A1 (en) | Novel multi-specific molecules | |
| JPWO2021181366A5 (https=) | ||
| CA3243623A1 (en) | Immunoconjugated and its use | |
| JPWO2021240388A5 (https=) | ||
| WO2025085857A1 (en) | Sirp antibodies for treatment of cancer | |
| US20260055187A1 (en) | Methods and compositions for treating autoimmune, allergic and inflammatory diseases | |
| WO2023028715A1 (en) | Fc variant with high thermal stability and attenuated effector function | |
| JPWO2021213475A5 (https=) | ||
| JP7853939B2 (ja) | 二重特異性チェックポイント阻害剤抗体 | |
| JPWO2021216956A5 (https=) | ||
| Strohl | Isotype selection and Fc engineering: design and construction of fit-for-purpose therapeutic antibodies | |
| KR20240052030A (ko) | 높은 열 안정성 및 감쇠된 효과기 기능을 갖는 fc 변이체 | |
| WO2025151607A1 (en) | Methods and compositions for treating autoimmune, allergic and inflammatory diseases |